


Oncology
2023-04-21

Deleting the MHC I (H2K1, H2D1) and MHC Il (H2Ab1) genes created an in vivo environment that prolonged survival and reduced GvHD occurrence upon human PBMC engraftment. This ultimately allows for a more extended study observation window. In this model, the half-life of IgG is maintained, unlike that in NCG-β2m
KO, which will give a better pharmacodynamic and pharmacokinetic study. In conclusion, the NCG-MHC-dKO is a suitable model for preclinical lgG antibody evaluation and PBMC reconstitution.
More infomation about blogs

Let us know which event you're attending and we'd be happy to connect with you.
This website will store cookies on your computer. These cookies are used to collect information about how you interact with this website and enable us to remember you. We use this information to improve and customize your browsing experience, as well as to analyze and collect relevant data and metrics about visitors on this website and other platforms. For more information about the cookies we use, please refer to our privacy policy
If you decline, your information will not be tracked when visiting this website. A cookie will be used in your browser to remember your preference settings that you have not accepted.
